Fmr LLC Buys 182,174 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

FMR LLC raised its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 2.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,618,297 shares of the company's stock after purchasing an additional 182,174 shares during the period. FMR LLC owned 7.84% of Atea Pharmaceuticals worth $22,171,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BML Capital Management LLC boosted its holdings in shares of Atea Pharmaceuticals by 4.3% during the 3rd quarter. BML Capital Management LLC now owns 6,650,000 shares of the company's stock valued at $22,278,000 after purchasing an additional 274,379 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Atea Pharmaceuticals by 55.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 594,360 shares of the company's stock valued at $1,968,000 after purchasing an additional 211,428 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Atea Pharmaceuticals during the 2nd quarter valued at about $603,000. Almitas Capital LLC bought a new position in shares of Atea Pharmaceuticals during the 2nd quarter valued at about $4,271,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Atea Pharmaceuticals by 21.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 67,137 shares of the company's stock valued at $272,000 after purchasing an additional 11,968 shares during the last quarter. Institutional investors own 86.67% of the company's stock.

Insider Buying and Selling at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, CEO Jean-Pierre Sommadossi sold 33,941 shares of the business's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $4.05, for a total transaction of $137,461.05. Following the completion of the transaction, the chief executive officer now owns 5,890,053 shares in the company, valued at $23,854,714.65. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 17.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Morgan Stanley raised shares of Atea Pharmaceuticals from an "underweight" rating to an "equal weight" rating and increased their price target for the company from $2.00 to $6.88 in a report on Tuesday, August 13th. William Blair raised shares of Atea Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th.

Atea Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ:AVIR traded down $0.08 during trading on Tuesday, reaching $2.94. The company's stock had a trading volume of 909,469 shares, compared to its average volume of 296,488. Atea Pharmaceuticals, Inc. has a 12 month low of $2.75 and a 12 month high of $4.60. The firm's 50 day simple moving average is $3.38 and its two-hundred day simple moving average is $3.54. The stock has a market capitalization of $248.32 million, a PE ratio of -1.33 and a beta of 0.20.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.13. During the same quarter in the prior year, the company posted ($0.40) earnings per share. Research analysts anticipate that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.